Roth Capital reiterated a Buy rating and $171.00 price target on Ligand Pharma (NASDAQ: LGND) following the recent ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE